Amphastar Pharmaceuticals, Inc. plans a second OTC drug in an emergency medicine category like its Primatene Mist nasal spray, but unlike the asthma remedy, it won’t be the only one of a formulation available nonprescription in the US.
Amphastar plans in 2024 to submit to the Food and Drug Application an application to move its Rextovy 4mg naloxone...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?